PRO-PHARMACEUTICALS REPORTS DAVANAT DATA

A A

Pro-Pharmaceuticals has reported the results of its Phase I trial of Davanat, a proprietary polysaccharide polymer that enables the delivery of chemotherapy drugs to protein receptors on cancer cells.

The Phase I multicenter trial was conducted on cancer patients with advanced solid tumors that were not open to surgery, radiation, or chemotherapy and also, were not responding to radio-labeled, 5-Fluorouracil, and had a minimum of 12 weeks to live.

Davanat is a proprietary polysaccharide polymer comprised of mannose and galactose carbohydrates in a Carbosome formation that enables the target delivery of chemotherapy drugs to protein receptors (lectins) on cancer cells. Lectins are present in large amounts on the surface of metastatic tumor cells, and may mediate cell association, apoptosis and metastasis.